Contact Us    855-RIA-PLAN (855-742-7526)

PFE: Pfizer Inc. Stock

By | July 6, 2018
Print Friendly, PDF & EmailPrint Friendly

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 303,375.44
Enterprise Value ($M) 341,563.44
Book Value ($M) 70,315.00
Book Value / Share 12.53
Price / Book 4.31
NCAV ($M) -45,322.00
NCAV / Share -8.07
Price / NCAV -6.69

Profitability (mra)
Return on Invested Capital (ROIC) 0.18
Return on Assets (ROA) 0.13
Return on Equity (ROE) 0.30

Liquidity (mrq)
Quick Ratio 1.18
Current Ratio 1.39

Balance Sheet (mrq) ($M)
Current Assets 57,900.00
Assets 179,188.00
Liabilities 103,222.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13G State Street Corp 5.03 -4.37
02-10 13G/A Vanguard Group Inc 8.06 -0.44
01-29 13G/A BlackRock Inc. 7.10 -6.86

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2021-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2021 ☐ TRANSITION REPORT PURSUANT TO
2021-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2021 ☐ TRANSITION REPORT PURSUANT TO SE
2021-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2021 ☐ TRANSITION REPORT PURSUANT TO S
2021-02-25 10-K Annual Report – 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2022-01-21 5,142,367 34,971,192 14.70
2022-01-20 4,583,719 30,299,722 15.13
2022-01-19 3,063,685 21,265,918 14.41
2022-01-18 4,629,520 26,471,368 17.49

(click for more detail)

(click for list of largest short owners)

Similar Companies
NVS – Novartis AG OGN – Organon & Co.
PBH – Prestige Brands Holdings, Inc. PRGO – Perrigo Company PLC
QGEN – QIAGEN N.V.


Financial data and stock pages provided by
Fintel.io





Post Views: 0
2018/07/06

Also Read

stock_market
> Back to All Posts